FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

 

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): May 13, 2003

 

 

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

 

Massachusetts

  

0-10824

  

04-2297484

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification Number)

 

100 Beaver Street

Waltham, Massachusetts 02453

 

(Address of principal executive offices, including zip code)

 

(781) 398-2300

 

(Registrant’s telephone number, including area code)

 

 

Page 1 of 4 pages.

 

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits

 

99.1 Press Release issued by Genome Therapeutics Corp. on May 13, 2003.

 

Item  9.   DISCLOSURE FURNISHED PURSUANT TO ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On May 13, 2003, Genome Therapeutics Corp. issued a press release announcing its financial results for its first fiscal quarter ended March 29, 2003. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

The information in this Form 8-K is furnished under “Item 12. Results of Operations and Financial Condition” in accordance with SEC Release No. 33-8216. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

-2-

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By:

  

/s/    STEPHEN COHEN        

   

Name: Stephen Cohen

   

Title: Senior Vice President and Chief Financial Officer

 

 

Date: May 14, 2003

 

 

3

 

EXHIBIT INDEX

 

Exhibit Number

   

Description

99.1

   

Press Release issued by Genome Therapeutics Corp. on

    

May 13, 2003.

 

4